These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1299 related articles for article (PubMed ID: 15139787)
21. How effective are the usual treatments for Crohn's disease? Bebb JR; Scott BB Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694 [TBL] [Abstract][Full Text] [Related]
22. Comparative tolerability of treatments for inflammatory bowel disease. Stein RB; Hanauer SB Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348 [TBL] [Abstract][Full Text] [Related]
23. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. Panaccione R; Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666 [TBL] [Abstract][Full Text] [Related]
24. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Ruemmele FM; Veres G; Kolho KL; Griffiths A; Levine A; Escher JC; Amil Dias J; Barabino A; Braegger CP; Bronsky J; Buderus S; Martín-de-Carpi J; De Ridder L; Fagerberg UL; Hugot JP; Kierkus J; Kolacek S; Koletzko S; Lionetti P; Miele E; Navas López VM; Paerregaard A; Russell RK; Serban DE; Shaoul R; Van Rheenen P; Veereman G; Weiss B; Wilson D; Dignass A; Eliakim A; Winter H; Turner D; ; J Crohns Colitis; 2014 Oct; 8(10):1179-207. PubMed ID: 24909831 [TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Akobeng AK; Zachos M Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022 [TBL] [Abstract][Full Text] [Related]
26. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686 [TBL] [Abstract][Full Text] [Related]
27. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. Keating GM; Perry CM BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485 [TBL] [Abstract][Full Text] [Related]
28. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Sandborn WJ; Hanauer SB Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177 [TBL] [Abstract][Full Text] [Related]
29. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. Clemett D; Markham A Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042 [TBL] [Abstract][Full Text] [Related]
30. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
31. Corticosteroid-sparing treatments in patients with Crohn's disease. Plevy SE Am J Gastroenterol; 2002 Jul; 97(7):1607-17. PubMed ID: 12135008 [TBL] [Abstract][Full Text] [Related]
33. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Magro F; Portela F BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228 [TBL] [Abstract][Full Text] [Related]
34. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376 [TBL] [Abstract][Full Text] [Related]
35. Economic implications of biological therapies for Crohn's disease: review of infliximab. Bodger K Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132 [TBL] [Abstract][Full Text] [Related]
36. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis? Burakoff R Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S202-3. PubMed ID: 18816760 [No Abstract] [Full Text] [Related]